

Reimbursement Alert

2023 MEDICARE PHYSICIAN FEE SCHEDULE (PFS) FINAL RULE

This Alert includes the late December 2022 update partially reducing the initial Medicare final rule 2023 Conversion Factor cut and associated payment rates for venous insufficiency vein ablation modalities. The effective date remains January 1, 2023.

HIGHLIGHTS OF THE Final 2023 PFS Final Rule

- The Medicare Physician Fee Schedule Final Rule includes a 2.08% reduction to the Conversion Factor, from \$34.6062 to \$33.8872, a portion of the formula determining physician payment rates.
- Medicare moved forward with the second year of the 4-year phase in of the labor pricing update portion of the non-facility practice expense inputs resulting in further reductions for some procedures (see below).

COMPARISON OF MEDICARE 2023 PFS FINAL RULE NATIONAL UNADJUSTED FEE SCHEDULE RATES VS MEDICARE 2022 FINAL PFS NATIONAL UNADJUSTED FEE SCHEDULE RATES

Table 3: Physician Fee Schedule (PFS) CY2023 Final Rule Payment Rates											
Final 2023 PFS Rates Compared to Final 2022											
CPT® Code	Description	2022 Work RVU	2022 Total Office RVU	2022 Total Facility RVU	2022 Final Total Office Payment	2023 Work RVU	2023 Total Office RVU	2023 Total Facility RVU	2023 Final Total Office Payment	2023 vs 2022 Final \$\$ Change Total Payment	2023 vs 2022 Final % Change Office Total Payment
36465	Varithena: 1 vein	2.35	40.70	3.46	\$1,408	2.35	39.49	3.48	\$1,338	-\$70	-5%
36466	Varithena: >1 vein	3.00	44.99	4.50	\$1,557	3.00	42.63	4.49	\$1,445	-\$112	-7%
36470	Sclerotherapy: 1 vein	0.75	3.44	1.11	\$119	0.75	3.46	1.14	\$117	-\$2	-2%
36471	Sclerotherapy: >1 vein	1.50	5.98	2.21	\$207	1.50	5.98	2.23	\$203	-\$4	-2%
36473	ClariVein: 1st vein	3.50	37.95	5.24	\$1,313	3.50	36.63	5.29	\$1,241	-\$72	-5%
36474	ClariVein: Each add'l vein	1.75	7.85	2.61	\$272	1.75	7.71	2.63	\$261	-\$10	-4%
36475	RF: 1st vein	5.30	33.38	8.13	\$1,155	5.30	32.47	8.13	\$1,100	-\$55	-5%
36476	RF: Each add'l vein	2.65	8.69	3.94	\$301	2.65	8.51	3.92	\$288	-\$12	-4%
36478	Laser: 1st vein	5.30	30.44	8.11	\$1,053	5.30	29.47	8.12	\$999	-\$55	-5%
36479	Laser: Each add'l vein	2.65	9.11	3.98	\$315	2.65	8.98	3.96	\$304	-\$11	-3%
36482	Venaseal: 1st vein	3.50	51.84	5.26	\$1,794	3.50	50.38	5.22	\$1,707	-\$87	-5%
36483	Venaseal: Each add'l vein	1.75	4.08	2.62	\$141	1.75	4.07	2.59	\$138	-\$3	-2%
37765	Stab phleb Veins Extr 10-20	4.80	12.89	7.97	\$446	4.80	12.64	7.94	\$428	-\$18	-4%
37766	Stab phleb veins extr 20+	6.00	15.01	9.76	\$519	6.00	14.85	9.74	\$503	-\$16	-3%

SOURCES

2022 CMS Final Rule Notices and Relative Value Files: [CMS-1751-F](#) | [CMS](#)

2023 CMS Final Rule Notices and Relative Value Files: [CMS-1770-F](#) | [CMS](#)

2023 CMS Relative Value Files RVU23A



Please see page 2 for important information about this Reimbursement Alert.

IMPORTANT INFORMATION

Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules, and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. **It is always the provider's sole responsibility to determine medical necessity, the proper site for delivery of any services, and to submit appropriate codes, charges, and modifiers for services that are rendered.** It is also always the provider's responsibility to understand and comply with Medicare national coverage determinations (NCD), Medicare local coverage determinations (LCD), and any other coverage requirements established by relevant payers which can be updated frequently. Boston Scientific recommends that you consult with your payers, reimbursement specialists, and/or legal counsel regarding coding, coverage, and reimbursement matters. Boston Scientific does not promote the use of its products outside their FDA-approved label.

Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding, or site of service requirements.

This coding information may include codes for procedures for which Boston Scientific currently offers no cleared or approved products. In those instances, such codes have been included solely in the interest of providing users with comprehensive coding information and are not intended to promote the use of any Boston Scientific products for which they are not cleared or approved. The Health Care Provider (HCP) is solely responsible for selecting the site of service and treatment modalities appropriate for the patient based on medically appropriate needs of that patient and the independent judgment of the HCP.

CPT Copyright 2021 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors, and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.

U.S. Government Rights

This product includes CPT which is commercial technical data, which was developed exclusively at private expense by the American Medical Association (AMA), 330 North Wabash Avenue, Chicago, Illinois 60611. The AMA does not agree to license CPT to the Federal Government based on the license in FAR 52.227-14 (Data Rights - General) and DFARS 252.227-7015 (Technical Data - Commercial Items) or any other license provision. The AMA reserves all rights to approve any license with any Federal agency.

INDICATIONS

Varithena (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

IMPORTANT SAFETY INFORMATION

The use of Varithena is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease. Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately. Varithena can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis. Physicians administering Varithena must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena.

For Full Prescribing Information visit Varithena.com

Varithena[™] is a registered trademark of Boston Scientific. All other trademarks are property of their respective owners.

**Boston
Scientific**
Advancing science for life[™]

Peripheral Interventions
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

Medical Professionals:
PI.Reimbursement@bsci.com

To order product or for more information
contact customer service at 1.888.272.1001.

© 2023 Boston Scientific Corporation
or its affiliates. All rights reserved.

Please see page 2 for important information about this Reimbursement Alert.